Aleksi Tornio

Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records (2018)

Clinical Pharmacology and Therapeutics

Tornio A, Flynn R, Morant S, Velten E, Palmer CNA, MacDonald TM, Doney ASF

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects (2018)

Basic and Clinical Pharmacology and Toxicology

Neuvonen M, Tarkiainen EK, Tornio A, Hirvensalo P, Tapaninen T, Paile-Hyvarinen M, Itkonen MK, Holmberg MT, Karja V, Mannisto VT, Neuvonen PJ, Pihlajamaki J, Backman JT, Niemi M

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide (2018)

British Journal of Clinical Pharmacology

Doki K, Darwich AS, Achour B, Tornio A, Backman JT, Rostami-Hodjegan A

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Response to "Influence of Diabetes on Antiplatelet Drug Efficacy" (2018)

Tornio A, Palmer CNA, Doney ASF

(O2 Muu julkaisu )

Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics (2018)

Clinical Pharmacology and Therapeutics

Hirvensalo P, Tornio A, Neuvonen M, Tapaninen T, Paile-Hyvarinen M, Karja V, Mannisto VT, Pihlajamaki J, Backman JT, Niemi M

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions (2018)

Drug Metabolism and Disposition

Kahma H, Filppula AM, Neuvonen M, Tarkiainen EK, Tornio A, Holmberg MT, Itkonen MK, Finel M, Neuvonen PJ, Niemi M, Backman JT

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters (2017)

Expert Opinion on Drug Metabolism and Toxicology

Tornio A, Neuvonen PJ, Niemi M, Backman JT

(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))

A commonmissense variant of LILRB5 is associated with statin intolerance andmyalgia (2017)

European Heart Journal

Siddiqui MK, Maroteau C, Veluchamy A, Tornio A, Tavendale R, Carr F, Abelega NU, Carr D, Bloch K, Hallberg P, Yue QY, Pearson ER, Colhoun HM, Morris AD, Dow E, George J, Pirmohamed M, Ridker PM, Doney ASF, Alfirevic A, Wadelius M, Maitland-van der Zee AH, Chasman DI, Palmer CNA

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone (2016)

Drug Metabolism and Disposition

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population (2016)

Basic and Clinical Pharmacology and Toxicology

Pietarinen P, Tornio A, Niemi M

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Contact

Links

Areas of expertise

Publications

Sort by:

Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records (2018)

Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects (2018)

Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide (2018)

Response to "Influence of Diabetes on Antiplatelet Drug Efficacy" (2018)

Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics (2018)

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions (2018)

Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters (2017)

A commonmissense variant of LILRB5 is associated with statin intolerance andmyalgia (2017)

Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone (2016)

High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population (2016)